Agios Reports Business Highlights and Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Agios Pharma (AGIO) PT Raised to $55 at RBC Capital
August 2, 2024 6:21 AM EDTRBC Capital analyst Kennen MacKay raised the price target on Agios Pharma (NASDAQ: AGIO) to $55.00 (from $53.00) while maintaining a Outperform rating.
The analyst comments "AGIO reported its 2Q24 update concurrent with the ACTIVATE-KidsT (pediatric PKD) topline results which missed the prespecified... More
